Niwa Takuya, Aoki Yoshitaka, Kobayashi Kensuke, Suzuki Kento, Katsuragawa Takayuki, Mimuro Soichiro, Nakajima Yoshiki
Department of Anesthesiology and Intensive Care Medicine, Hamamatsu University School of Medicine, 1-20-1 Handayama, Chuo-Ku, Hamamatsu, Shizuoka, 431-3192, Japan.
J Anesth. 2025 Jun;39(3):456-464. doi: 10.1007/s00540-025-03486-x. Epub 2025 Mar 25.
This study aimed to assess the effect of pulmonary artery catheter (PAC) use on clinical outcomes in cardiovascular patients stratified by severity using the Acute Physiology and Chronic Health Evaluation (APACHE) III score.
This study was conducted at Hamamatsu University Hospital and included intensive care unit (ICU) patients with cardiovascular diseases from April 2019 to March 2024. Patients were stratified into overall, severe, and critically severe cohorts based on their APACHE III scores. PAC group included those with PAC use within 24 h of ICU admission, while non-users formed the control group. The primary outcome was in-hospital mortality, whereas the secondary outcomes included ICU mortality, initiation of renal replacement therapy, mechanical circulatory support-free days at day 28, and lengths of hospital and ICU stay. One-to-one propensity score matching was performed to adjust for baseline differences.
Of the 1,693 patients, matched pairs were created for 210, 136, and 62 in the overall, severe, and critically severe cohorts, respectively. In-hospital mortality did not differ significantly between PAC and control groups across all cohorts (overall: 8.6% vs. 10.0%, p = 0.61; severe: 14.0% vs. 14.0%, p > 0.99; critically severe: 22.6% vs. 25.8%, p = 0.68). Among secondary outcomes, PAC use was significantly associated with increased renal replacement therapy and prolonged ICU stays in the overall and critically severe cohorts.
PAC use was not associated with improved outcomes in critically ill patients with cardiovascular diseases, even among those with a high mortality risk, suggesting the need for further studies.
本研究旨在评估使用肺动脉导管(PAC)对根据急性生理学与慢性健康状况评估(APACHE)III评分分层的心血管疾病患者临床结局的影响。
本研究在滨松大学医院进行,纳入了2019年4月至2024年3月期间患有心血管疾病的重症监护病房(ICU)患者。根据APACHE III评分将患者分为总体、重度和极重度队列。PAC组包括在ICU入院后24小时内使用PAC的患者,未使用者组成对照组。主要结局是住院死亡率,次要结局包括ICU死亡率、开始肾脏替代治疗、第28天无机械循环支持天数以及住院和ICU住院时间。进行一对一倾向评分匹配以调整基线差异。
在1693例患者中,总体、重度和极重度队列分别创建了210、136和62对匹配组。在所有队列中,PAC组和对照组的住院死亡率无显著差异(总体:8.6%对10.0%,p = 0.61;重度:14.0%对14.0%,p>0.99;极重度:22.6%对25.8%,p = 0.68)。在次要结局中,在总体和极重度队列中,使用PAC与肾脏替代治疗增加和ICU住院时间延长显著相关。
使用PAC与心血管疾病危重症患者的结局改善无关,即使在高死亡风险患者中也是如此,这表明需要进一步研究。